Proven Efficacy of Tacrolimus for Facial and Intertriginous Psoriasis

Lebwohl, Mark; Freeman, Amy Krupnick; Chapman, Michael; Feldman, Steven R.; Hartle, Jennifer; Henning, Alice K.

doi:10.1001/archderm.141.9.1154

Cited by 27 publications

(26 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Derinin daha ince olduğu bölgelerde lokalize psoriasiste takrolimus merhemi etkili ve güvenilir bir tedavi seçeneği olabilir. Nitekim yüz ve intertrijinöz bölgeler gibi bölgelerde erişkin ve çocuklarda yapılan çeşitli çalışmalarda takrolimus merhem etkili bulunmuştur [5][6][7][8][9] . Hatta fleksural ve fasiyal psoriasiste topikal takrolimus topikal klobetazol butirat ve mometazon furat gibi topikal steroidlere sırasıyla eşdeğer ve üstün bulunmuştur 7,8 .…”

Section: Discussionunclassified

“…Bugün için endikasyonlu ve endikasyon dışı olarak pek çok deri hastalığında kullanılmaktadır. Psoriasiste topikal takrolimusun etkinliğinin değerlendirildiği çalışmalarda özellikle fasiyal, invers ve genital psoriasiste başarılı sonuçlar bildirilmiştir [5][6][7][8][9] . Bunun yanında kronik plak tipi psoriasiste etkinliği plaseboya benzer, plasebodan üstün ve potent steroidlere eşdeğer şeklinde çelişkili sonuçlar bildirilmektedir [10][11][12] .…”

Section: Introductionunclassified

See 1 more Smart Citation

Efficacy of 0.1% tacrolimus ointment in chronic plaque psoriasis: A randomized double-blind placebo-controlled study

Kaçar¹,

Başkan²,

Bolca³

et al. 2015

TURKDERM

View full text Add to dashboard Cite

Background and Design: Despite the development of effective systemic treatments and new biological agents for psoriasis nowadays, topical medications are still the mainstay of treatment. Topical calcineurin inhibitors are currently used in various skin diseases. We investigated the efficacy and safety of tacrolimus, which is an alternative in topical treatment, in comparison with the present medications in plaque psoriasis. Materials and Methods: This prospective double-blind placebo-controlled study was conducted in 24 patients with the diagnosis of plaque psoriasis who were seen in Uludağ University Hospital dermatology outpatient clinic. 0.1% tacrolimus ointment, 0.1% mometasone furoate ointment, 0.005% calcipotriol ointment and placebo in encrypted bottles were randomly applied under occlusion to 27 psoriatic plaques in test chambers, every other day, for a period of 19 days. Clinic sum scores, side effects, and epidermal thickness measured by superficial ultrasound were noted before and after treatment in all microplaques. Besides, histopathologic scoring and epidermal thickness were measured in 9 patients at the end of the study. Results: The clinic sum scores and ultrasonographic epidermal thickness at the end were both significantly lower than the beginning values in all microplaques (p<0.05). The reduction in these two values with tacrolimus were significantly higher than that with placebo (p<0.001), but no difference was observed with calcipotriol (p=0.287, p=0.813, respectively). On the other hand, the reduction in these values with mometasone

show abstract

Section: Discussionunclassified

Section: Introductionunclassified

Efficacy of 0.1% tacrolimus ointment in chronic plaque psoriasis: A randomized double-blind placebo-controlled study

Kaçar¹,

Başkan²,

Bolca³

et al. 2015

TURKDERM

View full text Add to dashboard Cite

show abstract

“…Mittlerweile liegen aber einige Pilotstudien vor, die eine Wirksamkeit von Tacrolimus enthaltenden Zubereitungen bei der inversen Psoriasis belegen [8,17,18,31,35]. Eine größere vehikelkontrollierte Studie ergab bei 2-mal täglicher Anwendung der 0,1igen Spezialität eine Wirksamkeit bei inverser Psoriasis im Gesicht bzw.…”

Section: > Pilotstudien Belegen Die Wirksamkeit Von Tacrolimus Enthalunclassified

“…in den Intertrigines. Dabei war bereits nach 8 Tagen eine Wirkung nachweisbar [18]. Eine retrospektive Fallstudie befasst sich mit der Wirksamkeit der 0,1igen Spezialität bei der kindlichen inversen Psoriasis.…”

Section: > Pilotstudien Belegen Die Wirksamkeit Von Tacrolimus Enthalunclassified

Calcineurininhibitoren zur topischen Therapie der Psoriasis

Wohlrab

2006

Hautarzt

View full text Add to dashboard Cite

There are numerous possibilities for specific antiinflammatory therapy of psoriasis. One option is the use of calcineurin inhibitors. To date, only systemic administration of cyclosporine A is approved for this indication. Nonetheless cyclosporine A, tacrolimus and pimecrolimus can all be classed as effective anti-inflammatory agents for the therapy of psoriasis. Unfortunately, the vehicles currently available do not insure adequate topical delivery of these substances. Clinical efficacy of the preparations can be proven only when additional penetration-promoting measures are used or penetration-facilitating conditions exist. The entire group can be expected to play a greater role in the topical therapy of psoriasis if advances in vehicles and delivery systems are made.

show abstract

“…Lesions often extend beyond the hairline involving the forehead, neck, ears and facial skin. Patients who exhibit facial psoriasis often complain about intense itching and suffer from psychosocial problems due to the high visibility of the lesions [4,5,6,7,8,9,10,11]. Facial involvement of psoriasis is a major therapeutic challenge and requires a treatment approach other than topical corticosteroids which are highly efficacious but carry the risk of skin atrophy with chronic use.…”

Section: Introductionmentioning

confidence: 99%

Pimecrolimus 1% Cream in the Treatment of Facial Psoriasis: A 16-Week Open-Label Study

et al. 2008

View full text Add to dashboard Cite

Background: Facial psoriasis requires a treatment approach other than topical corticosteroids which bear the risk of skin atrophy. Topical pimecrolimus has been shown to be effective in atopic eczema and recently in psoriasis. Objective: The aim of this open-label single-center investigator-initiated study was to evaluate the efficacy and safety of pimecrolimus 1% cream in patients with facial psoriasis. Methods: 20 adults with facial psoriasis were enrolled. Pimecrolimus 1% cream was applied twice daily to psoriatic lesions of the face over an 8-week period. An 8-week follow-up was added. Results: All clinical parameters showed a significant improvement after 8 and 16 weeks compared to baseline. Pimecrolimus 1% cream was effective and well tolerated. Conclusions: This is the first clinical study with a larger patient cohort reporting a relevant therapeutic effect and favorable safety profile of pimecrolimus 1% cream in facial psoriasis.

show abstract

Proven Efficacy of Tacrolimus for Facial and Intertriginous Psoriasis

Cited by 27 publications

References 6 publications

Efficacy of 0.1% tacrolimus ointment in chronic plaque psoriasis: A randomized double-blind placebo-controlled study

Efficacy of 0.1% tacrolimus ointment in chronic plaque psoriasis: A randomized double-blind placebo-controlled study

Calcineurininhibitoren zur topischen Therapie der Psoriasis

Pimecrolimus 1% Cream in the Treatment of Facial Psoriasis: A 16-Week Open-Label Study

Contact Info

Product

Resources

About